Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07016620 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

Study acronym: ECHOLASER
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Sep 1, 2026 → Jun 1, 2027
See other at-risk trials from The Cleveland Clinic

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 1, 2026 to Jun 1, 2027
    • Eligibility criteria shortened, about 14 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 4 of 4 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2026 to Jan 12, 2026
    • Site details revised
    v8
  3. Start date: Nov 1, 2025 to Jan 1, 2026
    • Primary completion date: Jun 1, 2026 to Sep 1, 2026
    • Study completion date: Jun 1, 2027 to Sep 1, 2027
    v7
  4. Start date: Oct 1, 2025 to Nov 1, 2025v6
  5. Start date: Sep 1, 2025 to Oct 1, 2025v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Aug 1, 2025 to Sep 1, 2025v4
  2. Start date: Jul 1, 2025 to Aug 1, 2025v3
  3. Start date: Jun 1, 2025 to Jul 1, 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or require further intervention due to lack of adequate relief of obstruction. Treatment of persistent obstruction after MIST therapy (BPH salvage therapy) typically requires surgical intervention like transurethral resection of prostate (TURP). This study proposes to evaluate the effectiveness of in-office transperineal laser ablation (TPLA) using the Echolaser system as a minimally invasive treatment option for these patients, potentially avoiding more invasive surgical procedures. The Cleveland Clinic sees a high volume of BPH salvage patients, making this an ideal setting for this research.
Trial Details
NCT Number NCT07016620
Lead Sponsor The Cleveland Clinic
Collaborators: Rocamed Inc
Conditions
(from sponsor)		 Benign Prostatic Hyperplasia (BPH)
Related terms Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov